STAT+: Medicare is spending far less than expected on new Alzheimer’s drugs

Medicare spending on new Alzheimer's drugs, Leqembi and Kisunla, is lower than expected due to challenges in administration, limited patient population, and severe side effects. Medicare does not forecast significant spending on these drugs in 2026 or 2027. The drugs have had little meaningful benefits despite their approval.